Recent vaccination announcements have led to some confusion. Four physicians weigh in on who should get vaccinated and when ...

Robert Malone, who believes the U.S. government has “reality-bending information-control capabilities,” will guide the future ...

A new type of mRNA vaccine is more adaptable to mutating viruses like SARS-CoV-2 and the bird flu, according to research from ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Scientists in India are making significant strides in protecting our beloved pets from COVID-19. The ICAR-National Veterinary ...

"As organizations dedicated to public health and evidence-based health care for pregnant patients, we are particularly ...

Proxy fight: Representative Stephen Lynch of Massachusetts is running to become the top Democrat on an important House ...